R. Tsai

Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability

This study uses CRISPR screens to identify factors regulating wild-type and mutant p53 stability, finding distinct regulators for different p53 mutants and their implications in cancer.

In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer

The paper uses in vivo CRISPR screens to identify Serpinb9 and Adam2 as genes regulating immune therapy response in lung cancer, showing their roles in immune suppression and enhancement.

In vivo CRISPR screens reveal SCAF1 and USP15 as novel drivers of pancreatic cancer

This study uses in vivo CRISPR screens to identify USP15 and SCAF1 as novel tumor suppressors in pancreatic cancer, with potential therapeutic implications.

Loss of epigenetic regulation disrupts lineage integrity, reactivatesmultipotency and promotes breast cancer

This study identifies epigenetic regulators as tumor suppressors in breast cancer by showing their loss leads to lineage infidelity and reactivation of lactation programs.

Comparison of heat-inactivated and infectious SARS-CoV-2 across indoor surface materials shows comparable RT-qPCR viral signal intensity and persistence

This study compares RT-qPCR signal intensity and persistence of heat-inactivated and infectious SARS-CoV-2 on different surfaces, showing similar decay patterns and enabling simplified environmental monitoring protocols.

Oxidation shuts down an auto-inhibitory mechanism of von Willebrand factor

This study investigates how methionine oxidation in von Willebrand factor (VWF) removes an auto-inhibitory mechanism, revealing that oxidation destabilizes the A1-A2 domain interface, unmasking the GpIb-binding site.

Comprehensive analysis of lncRNAs reveals candidate prognostic biomarkers in multiple cancer types

The paper identifies 179 prognostic lncRNAs across 29 cancer types using machine learning, showing their association with patient risk and tumor subtypes.

The Secretome of Liver X Receptor Agonist Treated Early Outgrowth Cells Decreases Atherosclerosis in Ldlr-/- Mice

This study shows that treating early outgrowth cells with an LXR agonist reduces atherosclerosis in mice and inhibits monocyte adhesion to endothelial cells.